{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:57:07Z","timestamp":1780509427893,"version":"3.54.1"},"reference-count":95,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The survival and proliferation of follicular lymphoma (FL) cells are strongly dependent on macrophages, because their presence is necessary for the propagation of FL cells in vitro. To this regard, as also shown for the majority of solid tumors, a high tissue content of tumor-associated macrophages (TAMs), particularly if showing a protumoral phenotype (also called M2), is strongly associated with a poor outcome among patients with FL treated with chemotherapy. The introduction of rituximab, an anti-CD20 antibody that can be used by TAMs to facilitate antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis, has challenged this paradigm. In the rituximab era, clinical studies have yielded conflicting results in FL, showing variable outcomes based on the type of regimen used. This highlighted, for the first time, that the impact of TAMs on the prognosis of patients with FL may depend on the administered treatment, emphasizing the need to better understand how currently available therapies affect macrophage function in FL. We summarize the impact of approved and novel therapies for FL, including radiation therapy, chemotherapy, anti-CD20 monoclonal antibodies, lenalidomide, and targeted agents, on the biology of TAMs and describe their effects on macrophage phagocytosis, polarization, and function. Although novel agents targeting the CD47\/SIRP\u03b1 axis are being developed and show promising activity in FL, a deeper understanding of macrophage biology and their complex pathways will help to develop novel and safer therapeutic strategies for patients with this type of lymphoma.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005722","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T16:35:36Z","timestamp":1632760536000},"page":"4303-4312","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Follicular lymphoma and macrophages: impact of approved and novel therapies"],"prefix":"10.1182","volume":"5","author":[{"given":"Sushanth","family":"Gouni","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6324-2096","authenticated-orcid":false,"given":"Mario L.","family":"Marques-Piubelli","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Strati","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma and"},{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"issue":"3","key":"2021102615243478200_B1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9975(08)80047-3","article-title":"Pathological and immunohistochemical studies of follicular lymphoma in two calves","volume":"103","author":"Ishino","year":"1990","journal-title":"J Comp Pathol."},{"issue":"3","key":"2021102615243478200_B2","first-page":"425","article-title":"Follicular large cell lymphoma. An immunophenotype study","volume":"123","author":"Garcia","year":"1986","journal-title":"Am J Pathol."},{"issue":"7","key":"2021102615243478200_B3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0046-8177(82)80003-8","article-title":"T-lymphocyte subsets in follicular lymphomas compared with those in non-neoplastic lymph nodes and tonsils","volume":"13","author":"Dvoretsky","year":"1982","journal-title":"Hum Pathol."},{"issue":"7","key":"2021102615243478200_B4","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.4049\/jimmunol.144.7.2550","article-title":"Induction of proliferation of human follicular (B type) lymphoma cells by cognate interaction with CD4+ T cell clones","volume":"144","author":"Umetsu","year":"1990","journal-title":"J Immunol."},{"issue":"6","key":"2021102615243478200_B5","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V82.6.1848.1848","article-title":"Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40\/stromal cell system","volume":"82","author":"Johnson","year":"1993","journal-title":"Blood."},{"issue":"21","key":"2021102615243478200_B6","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med."},{"issue":"7","key":"2021102615243478200_B7","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1442-2042.2000.00190.x","article-title":"Prognostic value of tumor-associated macrophage count in human bladder cancer","volume":"7","author":"Hanada","year":"2000","journal-title":"Int J Urol."},{"issue":"8","key":"2021102615243478200_B8","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.3390\/jcm9082500","article-title":"Correlation between tumor-associated macrophage and immune checkpoint molecule expression and its prognostic significance in cutaneous melanoma","volume":"9","author":"Kim","year":"2020","journal-title":"J Clin Med."},{"issue":"1","key":"2021102615243478200_B9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"Tumour-educated macrophages promote tumour progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat Rev Cancer."},{"issue":"6","key":"2021102615243478200_B10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood."},{"issue":"12","key":"2021102615243478200_B11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.it.2004.09.015","article-title":"The chemokine system in diverse forms of macrophage activation and polarization","volume":"25","author":"Mantovani","year":"2004","journal-title":"Trends Immunol."},{"issue":"11","key":"2021102615243478200_B12","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood-2011-08-370908","article-title":"Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes","volume":"119","author":"Guilloton","year":"2012","journal-title":"Blood."},{"issue":"15","key":"2021102615243478200_B13","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The prognostic impact of CD163-positive macrophages in follicular lymphoma: a study from the BC Cancer Agency and the Lymphoma Study Association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2021102615243478200_B14","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00277-020-04025-2","article-title":"Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life","volume":"99","author":"Sortais","year":"2020","journal-title":"Ann Hematol."},{"issue":"4","key":"2021102615243478200_B15","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021102615243478200_B16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/bjh.14201","article-title":"The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era","volume":"175","author":"Blaker","year":"2016","journal-title":"Br J Haematol."},{"issue":"3","key":"2021102615243478200_B17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccr.2013.02.013","article-title":"Macrophage regulation of tumor responses to anticancer therapies","volume":"23","author":"De Palma","year":"2013","journal-title":"Cancer Cell."},{"issue":"7","key":"2021102615243478200_B18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol."},{"issue":"8","key":"2021102615243478200_B19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3324\/haematol.2017.165415","article-title":"Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"102","author":"Stevens","year":"2017","journal-title":"Haematologica."},{"issue":"34","key":"2021102615243478200_B20","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021102615243478200_B21","doi-asserted-by":"crossref","first-page":"e2016041","DOI":"10.4084\/mjhid.2016.041","article-title":"Limited stage follicular lymphoma: current role of radiation therapy","volume":"8","author":"Filippi","year":"2016","journal-title":"Mediterr J Hematol Infect Dis."},{"issue":"13","key":"2021102615243478200_B22","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.2003.09.542","article-title":"High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas","volume":"21","author":"Haas","year":"2003","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021102615243478200_B23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0360-3016(01)01626-1","article-title":"A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment","volume":"51","author":"Girinsky","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2021102615243478200_B24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.trsl.2017.11.002","article-title":"The role of macrophage phenotype in regulating the response to radiation therapy","volume":"191","author":"Shi","year":"2018","journal-title":"Transl Res."},{"issue":"1","key":"2021102615243478200_B25","doi-asserted-by":"crossref","first-page":"18765","DOI":"10.1038\/srep18765","article-title":"Ionizing radiation modulates human macrophages towards a pro-inflammatory phenotype preserving their pro-invasive and pro-angiogenic capacities","volume":"6","author":"Pinto","year":"2016","journal-title":"Sci Rep."},{"issue":"4","key":"2021102615243478200_B26","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2007-01-067579","article-title":"In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma","volume":"110","author":"Knoops","year":"2007","journal-title":"Blood."},{"issue":"1","key":"2021102615243478200_B27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1200\/jco.2003.05.128","article-title":"Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B","volume":"21","author":"Peterson","year":"2003","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021102615243478200_B28","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-18-1393","article-title":"Mechanisms of lymphoma clearance induced by high-dose alkylating agents","volume":"9","author":"Lossos","year":"2019","journal-title":"Cancer Discov."},{"issue":"11","key":"2021102615243478200_B29","first-page":"3024","article-title":"Chemotherapy of malignant lymphoma with adriamycin","volume":"33","author":"Gottlieb","year":"1973","journal-title":"Cancer Res."},{"issue":"11","key":"2021102615243478200_B30","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1080\/1042819031000123564","article-title":"The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases","volume":"44","author":"Rigacci","year":"2003","journal-title":"Leuk Lymphoma."},{"issue":"7","key":"2021102615243478200_B31","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.3324\/haematol.2019.230649","article-title":"Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma","volume":"105","author":"Strati","year":"2020","journal-title":"Haematologica."},{"issue":"1","key":"2021102615243478200_B32","first-page":"61","article-title":"Role of host defense merchanisms in the antitumor activity of adriamycin and daunomycin in mice","volume":"63","author":"Mantovani","year":"1979","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"2021102615243478200_B33","first-page":"815","article-title":"In vitro and in vivo cytotoxicity of adriamycin and daunomycin for murine macrophages","volume":"37","author":"Mantovani","year":"1977","journal-title":"Cancer Res."},{"issue":"10","key":"2021102615243478200_B34","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4161\/cbt.29922","article-title":"Production of IL-1\u03b2 by bone marrow-derived macrophages in response to chemotherapeutic drugs: synergistic effects of doxorubicin and vincristine","volume":"15","author":"Wong","year":"2014","journal-title":"Cancer Biol Ther."},{"key":"2021102615243478200_B35","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3389\/fimmu.2019.01197","article-title":"IL-1 family members in cancer; two sides to every story","volume":"10","author":"Baker","year":"2019","journal-title":"Front Immunol."},{"issue":"9873","key":"2021102615243478200_B36","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet."},{"issue":"4","key":"2021102615243478200_B37","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/ijlh.13216","article-title":"Lymphocyte-monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low-grade B-cell lymphoma","volume":"42","author":"Shimono","year":"2020","journal-title":"Int J Lab Hematol."},{"key":"2021102615243478200_B38","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fimmu.2014.00514","article-title":"From monocytes to M1\/M2 macrophages: phenotypical vs. functional differentiation","volume":"5","author":"Italiani","year":"2014","journal-title":"Front Immunol."},{"issue":"10","key":"2021102615243478200_B39","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood."},{"issue":"4","key":"2021102615243478200_B40","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","article-title":"CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma","volume":"105","author":"Marcus","year":"2005","journal-title":"Blood."},{"issue":"12","key":"2021102615243478200_B41","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood."},{"issue":"16","key":"2021102615243478200_B42","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol."},{"issue":"19","key":"2021102615243478200_B43","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","article-title":"A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone","volume":"13","author":"Taskinen","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2021102615243478200_B44","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","article-title":"High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial","volume":"26","author":"Canioni","year":"2008","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021102615243478200_B45","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","article-title":"Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV","volume":"112","author":"Minard-Colin","year":"2008","journal-title":"Blood."},{"issue":"7","key":"2021102615243478200_B46","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","article-title":"M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro","volume":"182","author":"Leidi","year":"2009","journal-title":"J Immunol."},{"issue":"33","key":"2021102615243478200_B47","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.18632\/oncotarget.27698","article-title":"An integrative microenvironment approach for follicular lymphoma: roles of inflammatory cell subsets and immune-response polymorphisms on disease clinical course","volume":"11","author":"Assis-Mendon\u00e7a","year":"2020","journal-title":"Oncotarget."},{"issue":"10","key":"2021102615243478200_B48","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1158\/1535-7163.MCT-12-1182","article-title":"Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models","volume":"12","author":"Herter","year":"2013","journal-title":"Mol Cancer Ther."},{"issue":"22","key":"2021102615243478200_B49","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood."},{"issue":"14","key":"2021102615243478200_B50","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med."},{"issue":"5","key":"2021102615243478200_B51","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.4049\/jimmunol.1301249","article-title":"Glycoengineering of therapeutic antibodies enhances monocyte\/macrophage-mediated phagocytosis and cytotoxicity","volume":"192","author":"Herter","year":"2014","journal-title":"J Immunol."},{"issue":"7","key":"2021102615243478200_B52","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/leu.2016.352","article-title":"A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells [public correction appears in Leukemia. 2017;31(10):2278]","volume":"31","author":"Cheadle","year":"2017","journal-title":"Leukemia."},{"issue":"2","key":"2021102615243478200_B53","doi-asserted-by":"crossref","first-page":"e1386361","DOI":"10.1080\/2162402X.2017.1386361","article-title":"CD20-selective inhibition of CD47-SIRP\u03b1 \u201cdon\u2019t eat me\u201d signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab","volume":"7","author":"van Bommel","year":"2017","journal-title":"OncoImmunology."},{"issue":"10","key":"2021102615243478200_B54","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med."},{"issue":"14","key":"2021102615243478200_B55","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021102615243478200_B56","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.2020007994","article-title":"Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood."},{"issue":"2","key":"2021102615243478200_B57","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.15797","article-title":"Combination lenalidomide-rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma","volume":"185","author":"Chiu","year":"2019","journal-title":"Br J Haematol."},{"issue":"11","key":"2021102615243478200_B58","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1038\/s41375-018-0114-0","article-title":"Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway","volume":"32","author":"Busch","year":"2018","journal-title":"Leukemia."},{"issue":"13","key":"2021102615243478200_B59","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2014.57.5092","article-title":"Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021102615243478200_B60","doi-asserted-by":"crossref","first-page":"e595","DOI":"10.1038\/bcj.2017.70","article-title":"Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma","volume":"7","author":"Tracy","year":"2017","journal-title":"Blood Cancer J."},{"issue":"1","key":"2021102615243478200_B61","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/asheducation-2011.1.96","article-title":"Nurture versus nature: the microenvironment in chronic lymphocytic leukemia","volume":"2011","author":"Burger","year":"2011","journal-title":"Hematology (Am Soc Hematol Educ Program)."},{"issue":"14","key":"2021102615243478200_B62","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"16","key":"2021102615243478200_B63","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1182\/blood-2015-04-640805","article-title":"Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells","volume":"126","author":"Linley","year":"2015","journal-title":"Blood."},{"issue":"21","key":"2021102615243478200_B64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.V120.21.156.156","article-title":"The Bruton\u2019s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma","volume":"120","author":"Fowler","year":"2012","journal-title":"Blood."},{"issue":"2","key":"2021102615243478200_B65","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood."},{"issue":"16","key":"2021102615243478200_B66","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/blood-2015-04-640912","article-title":"DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma","volume":"126","author":"Amin","year":"2015","journal-title":"Blood."},{"issue":"24","key":"2021102615243478200_B67","doi-asserted-by":"crossref","first-page":"39218","DOI":"10.18632\/oncotarget.16836","article-title":"The Bruton\u2019s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages","volume":"8","author":"Ping","year":"2017","journal-title":"Oncotarget."},{"issue":"8","key":"2021102615243478200_B68","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.3390\/cancers12082303","article-title":"Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by ibrutinib via inhibition of JAK2","volume":"12","author":"Barbarino","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"4","key":"2021102615243478200_B69","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bjh.16424","article-title":"The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma","volume":"189","author":"Fowler","year":"2020","journal-title":"Br J Haematol."},{"key":"2021102615243478200_B70","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.1200\/JCO.2018.36.15_suppl.7549","article-title":"Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL)","volume":"36","author":"Fowler","year":"2018","journal-title":"J Clin Oncol."},{"issue":"10","key":"2021102615243478200_B71","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.3324\/haematol.2017.169334","article-title":"The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies","volume":"102","author":"Golay","year":"2017","journal-title":"Haematologica."},{"issue":"4","key":"2021102615243478200_B72","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica."},{"issue":"35","key":"2021102615243478200_B73","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma [public correction appears in J Clin Oncol. 2018;36(5):521]","volume":"35","author":"Dreyling","year":"2017","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021102615243478200_B74","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: a phase II study of duvelisib (IPI-145) in patients with refractory indolent non-Hodgkin lymphoma [public correction appears in J Clin Oncol. 2019;37(16):1448]","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol."},{"issue":"4","key":"2021102615243478200_B75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol."},{"issue":"17","key":"2021102615243478200_B76","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/bloodadvances.2020001584","article-title":"PI3K\u03b4 inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax","volume":"4","author":"Serrat","year":"2020","journal-title":"Blood Adv."},{"issue":"7629","key":"2021102615243478200_B77","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression [public correction appears in Nature. 2017;542:124]","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature."},{"issue":"7629","key":"2021102615243478200_B78","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nature20554","article-title":"Overcoming resistance to checkpoint blockade therapy by targeting PI3K\u03b3 in myeloid cells","volume":"539","author":"De Henau","year":"2016","journal-title":"Nature."},{"issue":"8","key":"2021102615243478200_B79","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood."},{"issue":"18","key":"2021102615243478200_B80","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood."},{"issue":"11","key":"2021102615243478200_B81","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"issue":"12","key":"2021102615243478200_B82","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.celrep.2016.08.051","article-title":"IFN-\u03b3 induces histone 3 lysine 27 trimethylation in a small subset of promoters to stably silence gene expression in human macrophages","volume":"16","author":"Qiao","year":"2016","journal-title":"Cell Rep."},{"issue":"15","key":"2021102615243478200_B83","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1182\/blood-2015-02-625152","article-title":"CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells","volume":"125","author":"Am\u00e9-Thomas","year":"2015","journal-title":"Blood."},{"issue":"8","key":"2021102615243478200_B84","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol."},{"issue":"23","key":"2021102615243478200_B85","first-page":"2628","article-title":"Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed\/refractory follicular lymphoma","volume":"136","author":"Zinzani","year":"2020","journal-title":"Blood."},{"issue":"2","key":"2021102615243478200_B86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell."},{"issue":"5","key":"2021102615243478200_B87","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","article-title":"Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma","volume":"142","author":"Chao","year":"2010","journal-title":"Cell."},{"issue":"10","key":"2021102615243478200_B88","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-019-0246-0","article-title":"SIRP\u03b1 expression delineates subsets of intratumoral monocyte\/macrophages with different functional and prognostic impact in follicular lymphoma","volume":"9","author":"Chen","year":"2019","journal-title":"Blood Cancer J."},{"issue":"18","key":"2021102615243478200_B89","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med."},{"issue":"8","key":"2021102615243478200_B90","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","article-title":"Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies","volume":"27","author":"Ansell","year":"2021","journal-title":"Clin Cancer Res."},{"key":"2021102615243478200_B91","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-135941","article-title":"ALX148, a CD47 blocker, in combination with rituximab in patients with non-Hodgkin lymphoma","volume":"136","author":"Kim","year":"2020","journal-title":"Blood."},{"key":"2021102615243478200_B92","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in anti-tumor treatments targeting the CD47\/SIRP\u03b1 axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol."},{"issue":"4","key":"2021102615243478200_B93","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cac2.12023","article-title":"Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy","volume":"40","author":"Tan","year":"2020","journal-title":"Cancer Commun (Lond)."},{"key":"2021102615243478200_B94","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1182\/blood-2019-125315","article-title":"Dynamics of the cutaneous T cell lymphoma microenvironment in patients treated with pembrolizumab revealed by highly multiplexed tissue imaging","volume":"134","author":"Schuerch","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2021102615243478200_B95","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3324\/haematol.2014.113217","article-title":"Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia","volume":"100","author":"Fiorcari","year":"2015","journal-title":"Haematologica."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4303\/1830449\/advancesadv2021005722.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4303\/1830449\/advancesadv2021005722.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T08:38:57Z","timestamp":1673339937000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/20\/4303\/477039\/Follicular-lymphoma-and-macrophages-impact-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":95,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,10,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005722","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]}}}